Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$115.67

-0.32 (-0.28%)

, LOXO

Loxo Oncology

$232.56

0.055 (0.02%)

15:32
01/11/19
01/11
15:32
01/11/19
15:32

Lilly CEO says will leave CAR-T therapies to others, Reuters says

Eli Lilly (LLY) CEO Dave Ricks said that the company will leave CAR-T therapies for cancer and gene therapies for rare diseases to others, as the company seeks deals to enhance its pipeline of future treatments, Reuters reports. "The data is amazing, but practically, it's not reaching many people," Ricks said of CAR-T therapy in an interview with Reuters. The comments come after the company announced an $8B purchase of Loxo Oncology (LOXO) this week, the report says. Reference Link

LLY

Eli Lilly

$115.67

-0.32 (-0.28%)

LOXO

Loxo Oncology

$232.56

0.055 (0.02%)

  • 14

    Jan

  • 28

    Jan

  • 18

    May

LLY Eli Lilly
$115.67

-0.32 (-0.28%)

01/08/19
SBSH
01/08/19
DOWNGRADE
Target $235
SBSH
Neutral
Loxo Oncology downgraded to Neutral from Buy at Citi
Citi analyst Yigal Nochomovitz downgraded Loxo Oncology (LOXO) to Neutral saying the company is unlikely to receive a competing takeover bid. The analyst raised his price target for the shares to $235 from $201 to reflect the takeover agreement by Eli Lilly (LLY). He believes Mirati Therapeutics (MRTX) is another potential takeover candidate in the oncology space.
01/07/19
PIPR
01/07/19
NO CHANGE
Target $235
PIPR
Overweight
Piper Jaffray views price paid for Loxo by Eli Lilly as fair
Piper Jaffray analyst Tyler Van Buren views the price of $235 per share paid by Eli Lilly (LLY) for Loxo Oncology (LOXO) as fair. The analyst says the price is near the $250-plus he previously thought was achievable in an acquisition scenario for Loxo. Other names in the precision medicine/oncology space that could be up today as a result of the buyout are Agios Pharmaceuticals (AGIO), ArQule (ARQL), Array BioPharma (ARRY), Blueprint Medicines (BPMC), Kura Oncology (KURA), Mirati Therapeutics (MRTX) and others, Van Buren tells investors in a research note. He raised his price target for Loxo Oncology to $235 from $200 and keeps an Overweight rating on the shares.
12/31/18
CANT
12/31/18
NO CHANGE
Target $53
CANT
Overweight
Doctors impressed by tanezumab data, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen says that investors she's spoken with are expecting the data for Pfizer (PFE) and Eli Lilly's (LLY) tanezumab in the first half of 2019 to be similar to or worse than what was seen in the first Phase 3 data set reported on October 23. However, physicians are impressed by the data and do not believe the rapidly progressive osteoarthritis imbalance would impact their desire to prescribe tanezumab if it is approved, Chen tells investors in a research note. The analyst believes the safety for tanezumab will be better than expected and that the drug could replace opioids for the treatment of pain. If that is right, peak sales potential of tanezumab could be billions of dollars, and drive upside to modest expectations for the drug, says the analyst. She keeps an Overweight rating on Pfizer with a $53 price target.
12/27/18
ARGS
12/27/18
NO CHANGE
Target $135
ARGS
Buy
Argus sees volume growth, expanded indications as 2019 catalysts for Eli Lilly
Argus analyst David Toung kept his Buy rating and $135 price target on Eli Lilly, saying its 2019 catalysts for upside include anticipated volume growth and expanded indications for existing drugs, along with "potential regulatory approvals". The analyst notes that while the company's mature products are seeing slower sales and face patent expiration and the loss of exclusivity, he also expects Eli Lilly to generate earnings growth from margin expansion. Toung is also confident in 2019 contribution of Eli Lilly's recently launched Olumiant for rheumatoid arthritis, Verzenio for the second-line treatment of breast cancer, and Taltz for active psoriatic arthritis.
LOXO Loxo Oncology
$232.56

0.055 (0.02%)

11/28/18
SBSH
11/28/18
NO CHANGE
Target $201
SBSH
Buy
Loxo Oncology price target lowered to $201 from $213 at Citi
Citi analyst Yigal Nochomovitz lowered his price target for Loxo Oncology to $201 from $213 while keeping a Buy rating on the shares. The analyst says that with the adult price-point of $32,800 for Vitrakvi appearing the highest announced-to-date for a targeted/precision cancer therapy, he removed his estimate for 5% year-over-year price increases.
11/27/18
STFL
11/27/18
NO CHANGE
Target $230
STFL
Buy
Bayer's pricing for Vitrakvi 'breaking paradigm,' but justified, says Stifel
After the FDA granted accelerated approval to Loxo (LOXO) and Bayer's (BAYRY) Vitrakvi, Stifel analyst Stephen Willey said Bayer's reported price of $393,600/year is likely to generate some debate as it "appears to be breaking the small molecule oncology drug pricing paradigm." However, Willey believes the pricing decision is justified since Vitrakvi "has also shattered the efficacy paradigm for targeted oncology therapy." The $32,800/month price tag, according to media reports, is more than twice his launch pricing estimate, noted Willey, who said he must revisit his modeling assumptions. He has a Buy rating and $230 price target on Loxo Oncology shares.

TODAY'S FREE FLY STORIES

FB

Facebook

$164.25

-1.83 (-1.10%)

, GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

08:18
03/23/19
03/23
08:18
03/23/19
08:18
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

FB

Facebook

$164.25

-1.83 (-1.10%)

GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

GOOGL

Alphabet Class A

$1,206.00

-30.38 (-2.46%)

TWTR

Twitter

$32.98

0.37 (1.13%)

GM

General Motors

$36.51

-0.84 (-2.25%)

AMD

AMD

$26.43

-1.47 (-5.27%)

INTC

Intel

$53.20

-1.41 (-2.58%)

MRVL

Marvell

$19.69

-1.11 (-5.34%)

MCHP

Microchip

$85.50

-1.83 (-2.10%)

MU

Micron

$41.68

-2.32 (-5.27%)

NVDA

Nvidia

$177.40

-6.52 (-3.55%)

QCOM

Qualcomm

$56.71

-1.05 (-1.82%)

TXN

Texas Instruments

$109.51

-2.68 (-2.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 27

    Mar

  • 27

    Mar

  • 03

    Apr

  • 04

    Apr

  • 23

    Apr

  • 25

    Apr

  • 25

    Apr

  • 29

    Apr

  • 29

    Apr

  • 30

    Apr

  • 01

    May

  • 28

    May

  • 04

    Jun

  • 05

    Jun

  • 27

    Oct

21:30
03/22/19
03/22
21:30
03/22/19
21:30
General news
Breaking General news story  »

Chicago Federal Reserve…

21:15
03/22/19
03/22
21:15
03/22/19
21:15
General news
Breaking General news story  »

Atlanta Federal Reserve…

PLNT

Planet Fitness

$66.76

-0.825 (-1.22%)

18:44
03/22/19
03/22
18:44
03/22/19
18:44
Hot Stocks
Planet Fitness CEO: We have a streamlined business model »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRDM

Iridium

$26.40

-0.38 (-1.42%)

18:22
03/22/19
03/22
18:22
03/22/19
18:22
Hot Stocks
Iridium CEO: We've doubled our bottom line over the past eight years »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

18:05
03/22/19
03/22
18:05
03/22/19
18:05
General news
Sen. Sanders calls on White House to make Mueller report public »

U.S. Senator and…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$279.37

-5.26 (-1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDTI

Integrated Device

$47.80

-0.04 (-0.08%)

, RNECY

Renesas

$0.00

(0.00%)

18:02
03/22/19
03/22
18:02
03/22/19
18:02
Hot Stocks
Integrated Device, Renesas receive final approval for merger »

Renesas Electronics…

IDTI

Integrated Device

$47.80

-0.04 (-0.08%)

RNECY

Renesas

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

17:48
03/22/19
03/22
17:48
03/22/19
17:48
General news
Senator Warren urges AG Barr to release Mueller report to the public »

U.S. Senator and…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$279.37

-5.26 (-1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$362.49

-10.2 (-2.74%)

17:44
03/22/19
03/22
17:44
03/22/19
17:44
Hot Stocks
Lawmaker urges FAA, Boeing workers to utilize whistleblower page »

Chair of the House…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

GLD

SPDR Gold Shares

$123.97

0.29 (0.23%)

17:44
03/22/19
03/22
17:44
03/22/19
17:44
Hot Stocks
SPDR Gold Shares holdings rise to 781.03MT from 778.09MT »

This is the highest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

17:40
03/22/19
03/22
17:40
03/22/19
17:40
General news
Weekly CFTC Commitment of Traders highlights »

10-YEAR U.S. TREASURY net…

ONEXF

Onex

$0.00

(0.00%)

17:35
03/22/19
03/22
17:35
03/22/19
17:35
Hot Stocks
Onex to acquire Gluskin Sheff »

Onex Corporation and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DZSI

DASAN Zhone

$12.10

-0.12 (-0.98%)

17:35
03/22/19
03/22
17:35
03/22/19
17:35
Syndicate
Breaking Syndicate news story on DASAN Zhone »

DASAN Zhone files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

REPH

Recro Pharma

$9.73

0.1 (1.04%)

17:35
03/22/19
03/22
17:35
03/22/19
17:35
Hot Stocks
Breaking Hot Stocks news story on Recro Pharma »

Recro Pharma trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Mar

DZSI

DASAN Zhone

$12.10

-0.12 (-0.98%)

17:35
03/22/19
03/22
17:35
03/22/19
17:35
Syndicate
Breaking Syndicate news story on DASAN Zhone »

DASAN Zhone files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

17:34
03/22/19
03/22
17:34
03/22/19
17:34
General news
White House says hasn't received, been briefed on Mueller report, WSJ says »

Following confirmation…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$279.37

-5.26 (-1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CATS

Catasys

$13.19

-0.39 (-2.87%)

17:26
03/22/19
03/22
17:26
03/22/19
17:26
Syndicate
Breaking Syndicate news story on Catasys »

Catasys files $50M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USWS

U.S. Well Services

$7.74

-0.54 (-6.52%)

17:20
03/22/19
03/22
17:20
03/22/19
17:20
Syndicate
Breaking Syndicate news story on U.S. Well Services »

U.S. Well Services files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADIL

Adial Pharmaceuticals

$2.97

-0.12 (-3.88%)

17:17
03/22/19
03/22
17:17
03/22/19
17:17
Syndicate
Breaking Syndicate news story on Adial Pharmaceuticals »

Adial Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STNG

Scorpio Tankers

$18.85

-0.66 (-3.38%)

17:16
03/22/19
03/22
17:16
03/22/19
17:16
Syndicate
Breaking Syndicate news story on Scorpio Tankers »

Scorpio Tankers files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAVB

Navidea

$0.14

-0.0001 (-0.07%)

17:13
03/22/19
03/22
17:13
03/22/19
17:13
Syndicate
Navidea offers to sell $3M in common stock for existing shareholder »

Navidea…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

17:11
03/22/19
03/22
17:11
03/22/19
17:11
General news
Mueller delivers Russia report to AG William Barr, CNBC reports »

Special counsel Robert…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$279.37

-5.26 (-1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$362.49

-10.2 (-2.74%)

, NOC

Northrop Grumman

$268.29

-4.01 (-1.47%)

17:10
03/22/19
03/22
17:10
03/22/19
17:10
Hot Stocks
Boeing awarded $4.14B Missle Defense Agency contract »

Boeing (BA) has been…

BA

Boeing

$362.49

-10.2 (-2.74%)

NOC

Northrop Grumman

$268.29

-4.01 (-1.47%)

RTN

Raytheon

$179.98

-1.94 (-1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

AAPL

Apple

$190.97

-4.1 (-2.10%)

17:09
03/22/19
03/22
17:09
03/22/19
17:09
Periodicals
Partners not sure how Apple plans to package, price video service, CNBC says »

Apple is set to announce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

RIVE

Riverview Financial

$11.20

(0.00%)

17:05
03/22/19
03/22
17:05
03/22/19
17:05
Syndicate
Breaking Syndicate news story on Riverview Financial »

Riverview Financial files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.